Investigator-driven clinical research

Clinical patient-oriented research is under strain in many countries, including the Netherlands. There are a number of reasons for this. The demand for greater efficiency in healthcare systems leaves little time for investigator-driven clinical research, and the expanding burden of bureaucracy is creating growing obstacles. As a result, the research agenda for therapeutic clinical research is driven by pharmaceutical and other companies, and important clinical and scientific questions are not always being addressed. Improving efficient investigator-initiated clinical research requires both specialised competences and an advanced infrastructure.

You'll find the presentations here:

Trends

• John W. A. Eikelboom, MD, PhD, McMaster University, Hamilton, Canada
  International trends in clinical intervention research
• Prof. Huib Pols, MD, Erasmus MC, Rotterdam, The Netherlands
  Position of clinical intervention research in the Netherlands and recent trends

Sponsor- and investigator-driven research

• Prof. Jan P. Vandenbroucke, MD, University Medical Center, Leiden, TheNetherlands
  Sponsor- versus investigator-initiated clinical intervention research
• Prof. Harry R. Büller, MD, AMC, Amsterdam, The Netherlands
  How to find a balance between sponsors and investigators in clinical intervention research?
• Pauline Williams, MD, PhD, Head of the Academic Drug Performance Unit, GlaxoSmithKline
  What do pharmaceutical companies need from independent investigators?

Requirements for IDCR

• Prof. George E. Griffin, MD, St George's University of London, United Kingdom
  Good clinical practice guidelines and the European directive: how can investigator-initiated research survive?
• Prof. Adam F. Cohen, Center for Human Drug Research, Leiden, The Netherlands
  Requirements for early phase drug research
• Kirsten Steinhausen, PhD, German Research Association/German Ministry of Education and Research, Berlin
  Infrastructure requirements of investigator-initiated trials
• Prof. Jos W.M. van der Meer, vice-president of the Academy 
  Closing Remarks